Discover investment opportunities in Top 3 Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 3 Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 3 Stocks Under $3 using our Smart AI Filter.
5 stocks found for "Top 3 Stocks Under $3"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.19 | ±88.4% | -5.2 | 0.00% | |||
0.44 | ±100.0% | -0.4 | 0.00% | |||
1.40 | ±59.3% | -45.5 | 0.00% | |||
1.19 | ±71.0% | -1.1 | 0.00% | |||
0.79 | ±46.9% | -62.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read moreQ: What factors might impact the performance of Western Copper and Gold Corp (WRN)?
A: WRN's performance is heavily influenced by copper and gold prices, exploration success, and geopolitical stability in mining regions. As a small-cap stock, it may also experience higher volatility compared to larger counterparts.
Q: Is RVL Pharmaceuticals (RVPH) considered a growth stock?
A: While RVPH focuses on developing therapies in the pharmaceutical sector, its growth potential depends on novel drug approvals and market adoption. Investors should evaluate its R&D pipeline and competitive position.
Q: How does the uranium industry affect Denison Mines Corp's (DNN) stock price?
A: DNN's price is linked to uranium market dynamics, which include global demand for nuclear energy, regulatory changes, and uranium supply. Investors should assess how these factors could influence the sector.
Q: What are key considerations for investing in IMX Pharmaceuticals (IMUX)?
A: Investors should consider IMUX's clinical trial results, regulatory approvals, and partnership opportunities in immunotherapy. Market reception of its innovations may impact future revenue growth.
Q: How might geopolitical tensions influence HURA Uranium stocks?
A: Geopolitical issues can affect uranium supply chains and energy policy decisions, impacting HURA. Tracking global events and political climates could offer insights into potential investment risks and opportunities.
Q: Are Acutus Medical Inc (XAIR) operations internationally diversified?
A: XAIR concentrates on cardiac arrhythmia solutions primarily within North America. Limited geographical diversification may lead to operational risks tied to local healthcare policy changes.